REVA Medical Announces Successful MOTIV® Live Case Demonstration and Late-Breaking BTK Trial Results at VIVA26

Data ReadoutpositiveMOTIVPositive

AI Analysis

Summary

REVA Medical announced positive late-breaking results from its BTK trial showing MOTIV scaffolds achieved higher efficacy rates compared to balloon angioplasty in chronic limb-threatening ischemia patients, demonstrated via live case presentation at VIVA26 conference.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

MOTIV showed higher efficacy endpoint rates versus balloon angioplasty in both Rutherford 4 and Rutherford 5 CLTI populations in late-breaking BTK trial analysis

Importance:7/10

Sentiment:

0.80

MOTIV scaffoldBTK trialrevascularizationCLTIRutherford classificationVIVA26 conference

Related Companies

$MDCE

Read the original article

Published by PR Newswire Biotech on October 6, 2026 4:28 PM

Read Original